Trials / Recruiting
RecruitingNCT07405177
A Study of MK-7240 in Healthy Participants (MK-7240-009)
A Randomized, Open-label, Parallel-group Study to Assess the Pharmacokinetic Bioequivalence of Subcutaneously-administered Tulisokibart Delivered by 2 Different Autoinjectors in Healthy Participants
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 330 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study is to learn what happens to MK-7240 in a healthy person's body over time (pharmacokinetic or PK study). Researchers also want to learn about the safety of MK-7240 and if people tolerate it.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Tulisokibart Form 1 | Solution for injection. |
| BIOLOGICAL | Tulisokibart Form 2 | Solution for injection. |
Timeline
- Start date
- 2026-03-05
- Primary completion
- 2026-09-03
- Completion
- 2026-09-03
- First posted
- 2026-02-12
- Last updated
- 2026-04-08
Locations
2 sites across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07405177. Inclusion in this directory is not an endorsement.